December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Tom Powles: Cisplatin or Carboplatin-Based Chemotherapy with Pembrolizumab in Advanced Urothelial Cancer
Dec 8, 2024, 06:30

Tom Powles: Cisplatin or Carboplatin-Based Chemotherapy with Pembrolizumab in Advanced Urothelial Cancer

Tom Powles, Director of Barts Cancer Centre, shared a recent article on X:

“While EVP is better than platinum based chemotherapy in advanced bladder cancer, the debate whether cisplatin is much better than carboplatin goes on.

Here we show cisplatin combines a bit better with pembrolizumab than Carboplatin.

Matt Galsky maybe winning ESMOasia24.”

Title: Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study

Authors: Thomas Powles, Tibor Csőszi, Yohann Loriot, Nobuaki Matsubara, Lajos Geczi, Susanna Y-S Cheng, Yves Fradet, Ajjai Alva, Stéphane Oudard, Christof Vulsteke, Rafael Morales-Barrera, Aude Fléchon, Seyda Gunduz, Chih-Chin Liu, Blanca Homet Moreno, Abhishek Bavle and Mustafa Özgüroğlu

Tom Powles

Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre.

With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.

More posts featuring Tom Powles.